Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer Aeterna Zentaris Inc. , a late-stage medication development company specific in endocrine and oncology therapy, today reported benefits on the scientific activity of perifosine , the Company’s novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine ) as cure for advanced, metastatic colorectal cancer http://kamagrafrance.eu/des-herbes-pour-la-dysfonction-erectile.html .
This decrease reflects the influence of lower Commercial membership and efficiency and other improvements, partially offset by it spending related to the implementation of ICD-10 and HEALTHCARE Reform provisions and the inclusion of Medicity’s expenditures. The operating expense ratio was 18.7 % for the first quarter of 2011 and 18.6 % for the first quarter of 2010. Including net recognized capital benefits and litigation-related insurance proceeds received in 2010 2010, these %ages had been 18.6 % and 17.6 % for the first quarters of 2011 and 2010, respectively. Corporate Funding Interest Expense was $43.0 million and $39.6 million after tax for the first quarters of 2011 and 2010, respectively.